Search

• GlaxoSmithKline reaches agreement with Aspen to divest thrombosis brands and related manufacturing site for £0.7 billion

  Media

  Divestment supports strategic focus and delivery of pipeline.

  https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-reaches-agreement-with-aspen-to-divest-thrombosis-brands-and-related-manufacturing-site-for-07-billion/

  First published: 30 September 2013

• GSK announces US regulatory submission for fluticasone furoate monotherapy for asthma

  Media

  GSK announced the submission of a New Drug Application in the US for ICS treatment, FF administered using the ELLIPTA™ dry powder inhaler.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-regulatory-submission-for-fluticasone-furoate-monotherapy-for-asthma/

  First published: 23 October 2013

• GSK initiates voluntary open offer to increase stake in its pharmaceuticals subsidiary in India

  Media

  GSK today announced a Voluntary Open Offer to increase its stake in its publicly-listed pharmaceuticals subsidiary in India.

  https://www.gsk.com/en-gb/media/press-releases/gsk-initiates-voluntary-open-offer-to-increase-stake-in-its-pharmaceuticals-subsidiary-in-india/

  First published: 16 December 2013

• GSK and Genmab Receive Priority Review from FDA for Arzerra® (ofatumumab) as 1st Line Treatment for Chronic Lymphocytic Leukaemia (CLL)

  Media

  GSK and Genmab Receive Priority Review from FDA for Arzerra® (ofatumumab) as 1st Line Treatment for Chronic Lymphocytic Leukaemia (CLL)

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-priority-review-from-fda-for-arzerra-ofatumumab-as-1st-line-treatment-for-chronic-lymphocytic-leukaemia-cll/

  First published: 17 December 2013

• GSK completes divestment of thrombosis brands and related manufacturing site to Aspen

  Media

  GlaxoSmithKline (GSK) today completed the previously announced divestment of its thrombosis brands, ArixtraTM and FraxiparineTM.

  https://www.gsk.com/en-gb/media/press-releases/gsk-completes-divestment-of-thrombosis-brands-and-related-manufacturing-site-to-aspen/

  First published: 31 December 2013

• GSK statement on tender offer to acquire Human Genome Sciences

  Media

  GSK commented on HGS Board of Directors decision to recommend against GSK's offer to acquire all outstanding shares of HGS for US$13.00

  https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-tender-offer-to-acquire-human-genome-sciences/

  First published: 17 May 2012

• GlaxoSmithKline plc announces changes to its Board and Committees

  Media

  GlaxoSmithKline plc today announces the following changes to its Board and Committee structure.

  https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-announces-changes-to-its-board-and-committees/

  First published: 26 September 2012

• GSK’s Shingrix receives positive opinion from the CHMP in Europe for the prevention of shingles in adults aged 50 and over

  Media

  Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses, with a two-to-six month interval between doses.

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-shingrix-receives-positive-opinion-from-the-chmp-in-europe-for-the-prevention-of-shingles-in-adults-aged-50-and-over/

  First published: 26 January 2018

• Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over

  Media

  GSK announced the EC has approved Shingrix for the prevention of shingles & PHN in adults aged 50 years or older.

  https://www.gsk.com/en-gb/media/press-releases/shingrix-approved-in-europe-and-japan-for-the-prevention-of-shingles-in-adults-aged-50-and-over/

  First published: 23 March 2018

• CHMP recommend Nucala (mepolizumab) for the treatment of severe eosinophilic asthma paediatric patients in Europe

  Media

  GSK announced, EMA's CHMP is recommending Nucala as an add-on treatment for severe refractory eosinophilic asthma in paediatric patients.

  https://www.gsk.com/en-gb/media/press-releases/chmp-recommend-nucala-mepolizumab-for-the-treatment-of-severe-eosinophilic-asthma-paediatric-patients-in-europe/

  First published: 27 July 2018